CANDEL THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $24.12M, a 418.09% increase year-over-year.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $4.66M, a 34.73% increase year-over-year.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2025 was $5.04M, a 68.17% decline from fiscal 2024.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $15.83M.
- CANDEL THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $71.33M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $24.12M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.04M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $13.15M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $4.66M 10-Q · filed 2026-08-13 | $17.23M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $384.00K 10-Q · filed 2026-05-14 | $16.03M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $8.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $15.83M 10-K · filed 2026-03-12 |
| 2024-09-30 | $4.07M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $3.46M 10-Q · filed 2025-08-14 | |
| 2024-03-31 | $186.00K 10-Q · filed 2025-05-13 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $71.33M 10-K · filed 2023-03-30 |
| 2021-09-30 | $71.33M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |